Table 2

Clinical details of screen detected lung cancers

T0 outcomeStageVDT
(days)
Final stagePathology
(subtype)
Treatment
IndeterminatepT1a N0369IAAdenocarcinoma
(acinar)
Surgery
IndeterminatepT1a N0148IAAdenocarcinoma
(acinar)
Surgery
IndeterminatepT1a N089IASquamousSurgery
IndeterminatepT1a N0687*IAAdenocarcinoma
(acinar 50%, solid 20%, lepidic 30%)
Surgery
IndeterminatepT1a N0206IASquamousSurgery
IndeterminatepT1a N0285IAAdenocarcinoma
(micropapillary 50%, papillary 10%, lepidic 40%)
Surgery
Negative†pT1a N0142IAAdenocarcinoma
(solid 80%, acinar 20%)
Surgery
NegativecT1a N029‡IAClinicalSABR
Negative†cT1a N0163IAClinicalSABR
Negative†cT1a N051IANSCLC (NOS)SABR
NegativecT1a N071§IASquamousSABR
NegativecT1a N067§IAClinicalNo treatment¶
Negative†cT1b N065IAClinicalRadical radiotherapy
NegativepT2a N0IBAdenocarcinoma
(solid 80%, lepidic 20%)
Surgery
Negative†cT2a N072IBNSCLC (NOS)SABR
NegativecT1a N237‡IIIASquamousChemoradiotherapy(S)
NegativepT1a N286§IIIASmall cellSurgery/chemotherapy(A)
NegativecT4 N2 M1a34‡IVSmall cellChemoradiotherapy(S)
NegativecT3 N3 M1b16‡IVSmall cellChemoradiotherapy(S)
  • *Morphology of nodule changed with increasing density despite low VDT.

  • †False negative, (S)sequential treatment, (A)adjuvant chemotherapy.

  • ‡Estimated VDT.

  • §VDT calculated between T1 and T1+3-month surveillance scans.

  • ¶Had chemoradiotherapy for oesophageal cancer.

  • NOS, not otherwise specified; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy; VDT, volume doubling time.